1. P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. (2nd July 2019) Authors: Javle, M; Borbath, I; Clarke, S; Hitre, E; Louvet, C; Macarulla, T; Oh, D; Spratlin, J; Valle, J; Weiss, K; Berman, C; Howland, M; Ye, Y; Cho, T; Moran, S; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-134Antibodies matter: A meta-analysis of the prognostic value of human equilibrative nucleoside transporter 1 (hENT1) antibodies in pancreatobiliary cancer. (20th June 2018) Authors: Yusuf, D; Vos, L; Lui, A; Abdelaziz, Z; Ghosh, S; Spratlin, J; Mackey, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗